Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in multiple sclerosis (P1.393)

Conclusions:Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved in axon outgrowth and regeneration of the optic nerve, seem to be specific for a small subset of patients with multiple sclerosis.Disclosure: Dr. Hahn has nothing to disclose. Dr. Trendelenburg has nothing to disclose. Dr. Scharf has nothing to disclose. Dr. Denno has nothing to disclose. Dr. Brakopp has nothing to disclose. Dr. Teegen has nothing to disclose. Dr. Probst has nothing to disclose. Dr. Wandinger has nothing to disclose. Dr. Buttmann has received personal compensation from Almirall Hermal GmbH for serving on an advisory board. Dr. Szabados has nothing to disclose. Dr. vom Dahl has nothing to disclose. Dr. Kümpfel has nothing to disclose. Dr. Eichhorn has nothing to disclose. Dr. Gold has nothing to disclose. Dr. Paul has received received personal compensation for activities with Teva/Sanofi Aventis, Bayer Schering, Merck Serono, Biogen Idec, MedImmune and Novartis as a speaker. Dr. Jarius has nothing to disclose. Dr. Melzer has nothing to disclose. Dr. Stöcker has nothing to disclose. Dr. Komorowski has nothing to disclose.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Hahn, S., Trendelenburg, G., Scharf, M., Denno, Y., Brakopp, S., Teegen, B., Probst, C., Wandinger, K.-P., Buttmann, M., Szabados, F., vom Dahl, M., Kumpfel, T., Eichhorn, P., Gold, H.-J., Paul, F., Jarius, S., Melzer, N., Stocker, W., Komorowski, L. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis I Source Type: research